UBS Group
CLGN icon

UBS Group’s CollPlant Biotechnologies CLGN Stock Holding History

UBS Group’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361 Buy
104
+94
+940% +$362 ﹤0.01% 9897
2026
Q1 		$51 Buy
+10
New +$101 ﹤0.01% 10201
2025
Q2 		– Sell
-2,407
Closed -$62.1K – 10310
2025
Q1 		$62.1K Buy
2,407
+186
+8% +$6.55K ﹤0.01% 7414
2024
Q4 		$79.9K Buy
2,221
+1,026
+86% +$41.7K ﹤0.01% 7009
2024
Q3 		$59.3K Buy
1,195
+481
+67% +$23.6K ﹤0.01% 6703
2024
Q2 		$35.5K Buy
714
+236
+49% +$13.1K ﹤0.01% 6955
2024
Q1 		$25.6K Buy
+478
New +$25.8K ﹤0.01% 6806
2023
Q4 		– Sell
-569
Closed -$31.7K – 9365
2023
Q3 		$31.7K Sell
569
-86
-13% -$5.69K ﹤0.01% 6568
2023
Q2 		$53.4K Sell
655
-145
-18% -$10.6K ﹤0.01% 6438
2023
Q1 		$56.2K Buy
800
+96
+14% +$9.43K ﹤0.01% 6364
2022
Q4 		$58.8K Sell
704
-213
-23% -$14.6K ﹤0.01% 6606
2022
Q3 		$62K Buy
917
+166
+22% +$13.5K ﹤0.01% 6134
2022
Q2 		$60K Buy
751
+408
+119% +$37.5K ﹤0.01% 5777
2022
Q1 		$38K Sell
343
-184
-35% -$20.2K ﹤0.01% 6753
2021
Q4 		$86K Buy
+527
New +$94K ﹤0.01% 6449
2021
Q3 		– Sell
-201
Closed -$43K – 9586
2021
Q2 		$43K Buy
201
+83
+70% +$13.3K ﹤0.01% 6568
2021
Q1 		$16K Buy
+118
New +$17.8K ﹤0.01% 7564
2020
Q4 		– Sell
-27
Closed -$2K – 8417
2020
Q3 		$2K Sell
27
-43
-61% -$3.87K ﹤0.01% 7640
2020
Q2 		$7K Buy
+70
New +$7.21K ﹤0.01% 7213
2019
Q4 		– Sell
-530
Closed -$21K – 8127
2019
Q3 		$21K Buy
530
+352
+198% +$14.2K ﹤0.01% 6704
2019
Q2 		$8K Buy
+178
New +$9.34K ﹤0.01% 7177
2019
Q1 		– Sell
-332
Closed -$14K – 7765
2018
Q4 		$14K Sell
332
-651
-66% -$33.9K ﹤0.01% 7031
2018
Q3 		$50K Buy
+983
New +$54.2K ﹤0.01% 6160

Other funds holding CLGN

PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LWMI
Legacy Wealth Management (Idaho) Boise, Idaho $243M AUM 8.27% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $2.03B AUM 17.65% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group's CLGN Position: Q2 2026 in Review

UBS Group increased its CollPlant Biotechnologies (CLGN) stake by 940% in Q2 2026, buying an estimated $362 and bringing the position to 104 shares worth $361. The position accounts for ﹤0.01% of the portfolio, ranked #9897.

UBS Group first reported a position in CLGN in Q3 2018 and has held it in 23 quarters since. The position peaked at $86K in Q4 2021. 15 funds tracked by Wall St. Rank hold CLGN as of Q2 2026.

  • UBS Group held 104 shares of CollPlant Biotechnologies worth $361 as of Q2 2026.
  • UBS Group bought 94 CollPlant Biotechnologies shares in Q2 2026, an estimated $362.
  • CollPlant Biotechnologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9897 holding.
  • UBS Group first reported a position in CollPlant Biotechnologies in Q3 2018 and has held it in 23 quarters since.
  • UBS Group's CollPlant Biotechnologies position peaked at $86K in Q4 2021.
  • 15 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.